The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Clovis Oncology's quick ratio for the quarter that ended in Sep. 2022 was 0.12.
Clovis Oncology has a quick ratio of 0.12. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Clovis Oncology's Quick Ratio or its related term are showing as below:
CLVSQ's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.57 * Ranked among companies with meaningful Quick Ratio only.
Clovis Oncology Quick Ratio Historical Data
The historical data trend for Clovis Oncology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clovis Oncology's Quick Ratio
For the Biotechnology subindustry, Clovis Oncology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clovis Oncology's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clovis Oncology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Clovis Oncology's Quick Ratio falls into.
Clovis Oncology Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Clovis Oncology's Quick Ratio for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology (OTCPK:CLVSQ) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Clovis Oncology Quick Ratio Related Terms
Thank you for viewing the detailed overview of Clovis Oncology's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Clovis Oncology (Clovis Oncology) Business Description
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLVSQ has been successfully added to your 